Headquartered in Miami, FL Fiscal year ends December NASDAQ: SMMT smmttx.com
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of therapies for serious unmet medical needs in cancer. The company's lead asset is ivonescimab (SMT112), a potential first-in-class bispecific antibody that simultaneously blocks PD-1 (immunotherapy) and VEGF (anti-angiogenesis) in a single molecule, in-licensed from Akeso Inc. in January 2023. Summit holds exclusive rights to develop and commercialize ivonescimab in North America, South America, Europe, the Middle East, Africa, and Japan. The company is currently conducting four global Phase III clinical trials across non-small cell lung cancer and colorectal cancer indications (HARMONi, HARMONi-3, HARMONi-7, and HARMONi-GI3) and has a BLA under FDA review with a PDUFA date of November 14, 2026 for ivonescimab in EGFR-mutated NSCLC post-TKI. Summit has clinical collaborations with GSK, Revolution Medicines, Arcus Biosciences, and GORTEC, and supports over 65 investigator-sponsored trials at institutions including MD Anderson, Memorial Sloan Kettering, and Dana-Farber. The company is pre-revenue and pre-commercial, funding operations through equity offerings. Its shares trade on the Nasdaq Global Market under the symbol SMMT. Updated
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the…
After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho healthcare strategist Jared Holz reframed the sector, arguing that years of…
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company. Studies have shown that insider buys often lead…
In the past week or so, a gold and silver miner, an offshore driller, and a biotech saw some huge insider buying. These were not the only notable purchases.
The highlight of recent insider buying is an enormous purchase of Tesla shares by CEO Elon Musk. But it wasn't the only notable buy in the past week or so.
Insiders know their company the best. So, if they’re buying a good deal of shares, there’s often a reason for it. However, don’t buy a stock just because an insider is buying. …
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of therapies for serious unmet medical needs in cancer.
The Wall Street consensus 12-month price target for SMMT is $29.70. SMMT price prediction →
